Last edition
News about Engineering
Cleveland Clinic research identifies link between gut microbes and stroke
New findings from researchers at Cleveland Clinic, a top American hospital, show for the first time that the gut microbiome impacts stroke severity and functional impairment following stroke. The results, published in Cell Host & Microbe, lay the groundwork for potential new interventions to help treat or prevent stroke
Engineering | 22/06/2021 | By Darshana | 227
The Janssen Pharmaceutical Companies of Johnson & Johnson announced primary results from the pivotal phase 3 GLOW study (NCT03462719) evaluating fixed-duration Imbruvica plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukemia (CLL)
Engineering | 14/06/2021 | By Darshana | 252
CSIR-CDRI signs agreement with Marc Labs to develop drug for heart attack and stroke
The agreement has been signed for the development of a synthetic compound S-007-867 as modulator of blood coagulation cascade, in particular as inhibitor of collagen induced platelet aggregation. This may be helpful in treating patient population of coronary and cerebral artery diseases
Engineering | 12/06/2021 | By Darshana | 325
CSIR-IICT, Lee Pharma sign agreement to produce 2-D
Lee Pharma has entered into a non-exclusive licensing agreement with the Indian Institute of Chemical Technology (IICT), a constituent laboratory of CSIR, to manufacture and commercialise 2-Deoxy-D-Glucose (2-DG) recently developed by DRDO and Dr Reddy's Laboratories to treat COVID patients, informed a statement
Engineering | 11/06/2021 | By Darshana | 173
CMO Selkirk blueprints $90M factory to help bring injectable drug manufacturing stateside
Even as the pandemic winds down in the U.S., the push to bring drug manufacturing stateside persists. Privately held contract manufacturer Selkirk Pharma is teeing up a flagship facility in Washington state to do just that
Engineering | 10/06/2021 | By Darshana | 226
Zydus Cadila receives US FDA approval for fluphenazine HCl tablets
Zydus Cadila has received final approval from US FDA to market fluphenazine hydrochloride tablets in the strengths of 1 mg, 2.5 mg, 5 mg, and 10 mg (Prolixin tablets). This medication is used to treat symptoms of a certain type of mental/mood condition (schizophrenia)
Engineering | 31/05/2021 | By Darshana | 171
Bharat Biotech signs MoU with GCVC for drug substance for Covaxin
Bharat Biotech International Limited has signed an MoU with Gujarat Covid Vaccine Consortium (GCVC) towards contract manufacturing for the drug substance for Covaxin
Engineering | 28/05/2021 | By Darshana | 158
Moderna announced that the phase 2/3 study of its Covid-19 vaccine (mRNA-1273) in adolescents has met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination. In the study, no cases of Covid-19 were observed in participants
Engineering | 27/05/2021 | By Darshana | 165
Zydus Cadila launches Ujvira for breast cancer treatment
Zydus Cadila, a global innovation driven healthcare company, launched trastuzumab emtansine, the first antibody drug conjugate (ADC) biosimilar and a highly effective drug for treating both early and advanced HER2 positive breast cancer, under the brand name 'Ujvira'. HER2 positive breast cancer is considered an aggressive form and constitutes 20 to 25%
Engineering | 25/05/2021 | By Darshana | 458
Ambu to launch US FDA approved sterile, single-use duodenoscope, aScope Duodeno
The Ambu, a company develop, produce and market diagnostic and life-supporting devices for hospitals and rescue services, announced that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for aScope Duodeno on 17 July 2020 and is now ready for commercial launch as planned
Engineering | 20/07/2020 | By Darshana | 523
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy